|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
|
EP4282419A1
(en)
|
2012-12-20 |
2023-11-29 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
US9434935B2
(en)
|
2013-03-10 |
2016-09-06 |
Bellicum Pharmaceuticals, Inc. |
Modified caspase polypeptides and uses thereof
|
|
CA2912172A1
(en)
|
2013-06-05 |
2014-12-11 |
Bellicum Pharmaceuticals, Inc. |
Methods for inducing partial apoptosis using caspase polypeptides
|
|
CA2959168A1
(en)
|
2014-09-02 |
2016-03-10 |
Bellicum Pharmaceuticals, Inc. |
Costimulation of chimeric antigen receptors by myd88 and cd40 polypeptides
|
|
GB201503133D0
(en)
|
2015-02-24 |
2015-04-08 |
Ucl Business Plc And Syncona Partners Llp |
Chimeric protein
|
|
KR20180053744A
(ko)
|
2015-09-23 |
2018-05-23 |
사이토이뮨 테라퓨틱스 엘엘씨 |
면역 요법을 위한 flt3 유도된 car 세포
|
|
US12241053B2
(en)
|
2015-10-09 |
2025-03-04 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2017075465A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
|
|
WO2017075451A1
(en)
|
2015-10-28 |
2017-05-04 |
The Broad Institute Inc. |
Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
|
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
US12144850B2
(en)
|
2016-04-08 |
2024-11-19 |
Purdue Research Foundation |
Methods and compositions for car T cell therapy
|
|
US20190262399A1
(en)
|
2016-09-07 |
2019-08-29 |
The Broad Institute, Inc. |
Compositions and methods for evaluating and modulating immune responses
|
|
WO2018067991A1
(en)
|
2016-10-07 |
2018-04-12 |
The Brigham And Women's Hospital, Inc. |
Modulation of novel immune checkpoint targets
|
|
WO2018089386A1
(en)
|
2016-11-11 |
2018-05-17 |
The Broad Institute, Inc. |
Modulation of intestinal epithelial cell differentiation, maintenance and/or function through t cell action
|
|
US20200095547A1
(en)
*
|
2016-12-02 |
2020-03-26 |
Darya ALIZADEH |
Methods for manufacturing t cells expressing of chimeric antigen receptors and other receptors
|
|
KR102903340B1
(ko)
*
|
2017-01-06 |
2025-12-26 |
이오반스 바이오테라퓨틱스, 인크. |
종양 괴사 인자 수용체 슈퍼패밀리 (tnfrsf) 효능제를 사용한 종양 침윤 림프구 (til)의 확장 및 til과 tnfrsf 효능제의 치료 조합물
|
|
AU2018219226B2
(en)
|
2017-02-07 |
2024-12-19 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
US11963966B2
(en)
|
2017-03-31 |
2024-04-23 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating ovarian tumors
|
|
US11913075B2
(en)
|
2017-04-01 |
2024-02-27 |
The Broad Institute, Inc. |
Methods and compositions for detecting and modulating an immunotherapy resistance gene signature in cancer
|
|
WO2018191558A1
(en)
|
2017-04-12 |
2018-10-18 |
The Broad Institute, Inc. |
Modulation of epithelial cell differentiation, maintenance and/or function through t cell action, and markers and methods of use thereof
|
|
US20200071773A1
(en)
|
2017-04-12 |
2020-03-05 |
Massachusetts Eye And Ear Infirmary |
Tumor signature for metastasis, compositions of matter methods of use thereof
|
|
WO2018208849A1
(en)
|
2017-05-09 |
2018-11-15 |
Bellicum Pharmaceuticals, Inc. |
Methods to augment or alter signal transduction
|
|
WO2018209324A2
(en)
|
2017-05-11 |
2018-11-15 |
The Broad Institute, Inc. |
Methods and compositions of use of cd8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
|
|
WO2018232195A1
(en)
|
2017-06-14 |
2018-12-20 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
US20230190797A1
(en)
*
|
2017-06-30 |
2023-06-22 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for adoptive cell therapy
|
|
US12496310B2
(en)
|
2017-06-30 |
2025-12-16 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for adoptive cell therapy
|
|
CA3068636A1
(en)
|
2017-06-30 |
2019-01-03 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for adoptive cell therapy for cancer
|
|
CA3068634A1
(en)
|
2017-06-30 |
2019-01-03 |
Memorial Sloan Kettering Cancer Center |
Compositions and methods for adoptive cell therapy for cancer
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
CN107557337B
(zh)
*
|
2017-09-15 |
2020-06-26 |
山东兴瑞生物科技有限公司 |
一种抗ror1安全型嵌合抗原受体修饰的免疫细胞及其应用
|
|
WO2019070755A1
(en)
|
2017-10-02 |
2019-04-11 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
|
|
US11732257B2
(en)
|
2017-10-23 |
2023-08-22 |
Massachusetts Institute Of Technology |
Single cell sequencing libraries of genomic transcript regions of interest in proximity to barcodes, and genotyping of said libraries
|
|
WO2019094955A1
(en)
|
2017-11-13 |
2019-05-16 |
The Broad Institute, Inc. |
Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
|
|
EP3710039A4
(en)
|
2017-11-13 |
2021-08-04 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
|
|
CA3084190A1
(en)
|
2017-12-08 |
2019-06-13 |
Bellicum Pharmaceuticals, Inc. |
Methods for enhancing and maintaining car-t cell efficacy
|
|
CN111565737A
(zh)
|
2017-12-14 |
2020-08-21 |
蓝鸟生物公司 |
Daric白细胞介素受体
|
|
SG11202005307RA
(en)
*
|
2017-12-14 |
2020-07-29 |
Bluebird Bio Inc |
Nkg2d daric receptors
|
|
EP3728189A1
(en)
|
2017-12-20 |
2020-10-28 |
Bellicum Pharmaceuticals, Inc. |
Multimeric piperidine derivatives
|
|
US11994512B2
(en)
|
2018-01-04 |
2024-05-28 |
Massachusetts Institute Of Technology |
Single-cell genomic methods to generate ex vivo cell systems that recapitulate in vivo biology with improved fidelity
|
|
US11311576B2
(en)
|
2018-01-22 |
2022-04-26 |
Seattle Children's Hospital |
Methods of use for CAR T cells
|
|
WO2019147844A1
(en)
*
|
2018-01-25 |
2019-08-01 |
University Of Washington |
Engineered cell death-inducing enzymes and methods of use
|
|
WO2019156795A1
(en)
|
2018-02-06 |
2019-08-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
CA3091674A1
(en)
|
2018-02-23 |
2019-08-29 |
Endocyte, Inc. |
Sequencing method for car t cell therapy
|
|
CA3092794A1
(en)
|
2018-03-01 |
2019-09-06 |
University Of Kansas |
Techniques for generating cell-based therapeutics using recombinant t cell receptor genes
|
|
EP3759132A1
(en)
|
2018-03-02 |
2021-01-06 |
Allogene Therapeutics, Inc. |
Inducible chimeric cytokine receptors
|
|
CN112004924A
(zh)
|
2018-04-18 |
2020-11-27 |
Ucl商务有限公司 |
增强treg细胞抑制特性的方法
|
|
US11957695B2
(en)
|
2018-04-26 |
2024-04-16 |
The Broad Institute, Inc. |
Methods and compositions targeting glucocorticoid signaling for modulating immune responses
|
|
US12410231B2
(en)
|
2018-05-07 |
2025-09-09 |
Board Of Regents Of The University Of Texas System |
Natural killer cell products and methods
|
|
US12448426B2
(en)
|
2018-05-17 |
2025-10-21 |
St. Jude Children's Research Hospital, Inc. |
Chimeric antigen receptors with MYD88 and CD40 costimulatory domains
|
|
US20210371932A1
(en)
|
2018-06-01 |
2021-12-02 |
Massachusetts Institute Of Technology |
Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
|
|
US12036240B2
(en)
|
2018-06-14 |
2024-07-16 |
The Broad Institute, Inc. |
Compositions and methods targeting complement component 3 for inhibiting tumor growth
|
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
|
WO2020081730A2
(en)
|
2018-10-16 |
2020-04-23 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating microenvironment
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
US11739156B2
(en)
|
2019-01-06 |
2023-08-29 |
The Broad Institute, Inc. Massachusetts Institute of Technology |
Methods and compositions for overcoming immunosuppression
|
|
BR112021017365A2
(pt)
|
2019-03-01 |
2022-02-01 |
Allogene Therapeutics Inc |
Receptores de citocina quiméricos constitutivamente ativos
|
|
AU2020232216B2
(en)
|
2019-03-01 |
2025-09-25 |
Allogene Therapeutics, Inc. |
Chimeric cytokine receptors bearing a PD-1 ectodomain
|
|
WO2020186101A1
(en)
|
2019-03-12 |
2020-09-17 |
The Broad Institute, Inc. |
Detection means, compositions and methods for modulating synovial sarcoma cells
|
|
EP3942023A1
(en)
|
2019-03-18 |
2022-01-26 |
The Broad Institute, Inc. |
Compositions and methods for modulating metabolic regulators of t cell pathogenicity
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
WO2020243371A1
(en)
|
2019-05-28 |
2020-12-03 |
Massachusetts Institute Of Technology |
Methods and compositions for modulating immune responses
|
|
WO2021030627A1
(en)
|
2019-08-13 |
2021-02-18 |
The General Hospital Corporation |
Methods for predicting outcomes of checkpoint inhibition and treatment thereof
|
|
US12421557B2
(en)
|
2019-08-16 |
2025-09-23 |
The Broad Institute, Inc. |
Methods for predicting outcomes and treating colorectal cancer using a cell atlas
|
|
US12528856B2
(en)
|
2019-08-30 |
2026-01-20 |
Allogene Therapeutics, Inc. |
Chimeric cytokine receptors comprising TGF β binding domains
|
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
CA3156171A1
(en)
*
|
2019-09-30 |
2021-04-08 |
Candel Therapeutics, Inc. |
CANCER TREATMENT BY COMBINED GENE-MEDIATED CYTOTOXIC IMMUNOTHERAPY AND ATR INHIBITOR
|
|
US12297426B2
(en)
|
2019-10-01 |
2025-05-13 |
The Broad Institute, Inc. |
DNA damage response signature guided rational design of CRISPR-based systems and therapies
|
|
US12394502B2
(en)
|
2019-10-02 |
2025-08-19 |
The General Hospital Corporation |
Method for predicting HLA-binding peptides using protein structural features
|
|
US11981922B2
(en)
|
2019-10-03 |
2024-05-14 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
|
|
US12195725B2
(en)
|
2019-10-03 |
2025-01-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
|
|
US11793787B2
(en)
|
2019-10-07 |
2023-10-24 |
The Broad Institute, Inc. |
Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
|
|
US11844800B2
(en)
|
2019-10-30 |
2023-12-19 |
Massachusetts Institute Of Technology |
Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
|
|
US20240156864A1
(en)
*
|
2019-10-31 |
2024-05-16 |
The University Of North Carolina At Chapel Hill |
Methods and compositions for chimeric antigen receptor targeting cancer cells
|
|
US12165747B2
(en)
|
2020-01-23 |
2024-12-10 |
The Broad Institute, Inc. |
Molecular spatial mapping of metastatic tumor microenvironment
|
|
KR20220163940A
(ko)
|
2020-02-04 |
2022-12-12 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
항-디니트로페놀 키메라 항원 수용체
|
|
CA3167065A1
(en)
|
2020-02-24 |
2021-09-02 |
Regina Junhui LIN |
Bcma car-t cells with enhanced activities
|
|
JP2023522330A
(ja)
|
2020-04-17 |
2023-05-30 |
シティ・オブ・ホープ |
Ｆｌｔ３陽性悪性腫瘍を処置するためのｆｌｔ３標的化キメラ抗原受容体改変細胞
|
|
CN112156181A
(zh)
*
|
2020-09-29 |
2021-01-01 |
广州恩宝生物医药科技有限公司 |
一种腺病毒四价疫苗
|
|
CN120676952A
(zh)
|
2022-07-08 |
2025-09-19 |
维罗米梭公司 |
溶瘤痘苗病毒及其重组病毒和使用方法
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
WO2024124044A1
(en)
|
2022-12-07 |
2024-06-13 |
The Brigham And Women’S Hospital, Inc. |
Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
|
|
WO2024145622A1
(en)
*
|
2022-12-29 |
2024-07-04 |
Kelonia Therapeutics, Inc. |
Recombinant retroviruses, compositions, and methods of use
|
|
WO2024145605A1
(en)
*
|
2022-12-29 |
2024-07-04 |
Kelonia Therapeutics, Inc. |
Recombinant retroviruses, compositions, and methods of use
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025097055A2
(en)
|
2023-11-02 |
2025-05-08 |
The Broad Institute, Inc. |
Compositions and methods of use of t cells in immunotherapy
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|